Psoriasis and Vascular Risk: An Update

被引:19
作者
Katsiki, Niki [1 ]
Anagnostis, Panagiotis [1 ,2 ]
Athyros, Vasilios G. [1 ]
Karagiannis, Asterios [1 ]
Mikhailidis, Dimitri P. [3 ,4 ]
机构
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Sch Med, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece
[2] Police Med Ctr Northern Greece, Div Endocrinol, Thessaloniki, Greece
[3] UCL, Sch Med, Dept Clin Biochem, Vasc Dis Prevent Clin, London NW3 2QG, England
[4] UCL, Sch Med, Dept Surg, London NW3 2QG, England
关键词
Cardiovascular disease; metabolic syndrome; non-alcoholic fatty liver disease; psoriasis; psoriatic arthritis; vascular risk factors; ENDOTHELIAL GROWTH-FACTOR; CHRONIC PLAQUE PSORIASIS; OBSTRUCTIVE SLEEP-APNEA; SERUM URIC-ACID; PERIPHERAL ARTERIAL-DISEASE; FATTY LIVER-DISEASE; POST-HOC ANALYSIS; MYOCARDIAL-INFARCTION RISK; LIPOPROTEIN LDL SUBCLASSES; IMMUNE-MEDIATED DISEASES;
D O I
10.2174/1381612820666140417105323
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Psoriasis is a chronic systemic inflammatory disease characterized by topical skin lesions as well as an increased risk for cardiovascular disease (CVD). There is also increasing evidence that patients with psoriasis are more prone to several CVD risk factors (hypertension, obesity, dyslipidemia and smoking), non-cardiac vascular diseases (carotid, peripheral artery and chronic kidney disease) and metabolic co-morbidities (type 2 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease and obstructive sleep apnea) compared with the general population. The associations are even greater in patients with severe psoriasis and those with psoriatic arthritis. Insulin resistance, endothelial dysfunction and obesity induced by several adipokines and inflammatory cytokines are proposed as the common mechanisms linking psoriasis with CVD, vascular risk factors and metabolic diseases. The present narrative review considers the associations between psoriasis (and psoriatic arthritis) with CVD, vascular risk factors and metabolic diseases. Drugs that reduce CVD risk and improve metabolic parameters may also beneficially affect psoriasis severity and prognosis. Furthermore, anti-psoriatic drugs can exert different effects on CVD risk and metabolic co-morbidities. Therefore, physicians should be aware of these associations in order to adequately monitor and treat psoriatic patients.
引用
收藏
页码:6114 / 6125
页数:12
相关论文
共 277 条
[1]
Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK [J].
Abuabara, K. ;
Azfar, R. S. ;
Shin, D. B. ;
Neimann, A. L. ;
Troxel, A. B. ;
Gelfand, J. M. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (03) :586-592
[2]
Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study [J].
Ahlehoff, O. ;
Skov, L. ;
Gislason, G. ;
Lindhardsen, J. ;
Kristensen, S. L. ;
Iversen, L. ;
Lasthein, S. ;
Gniadecki, R. ;
Dam, T. N. ;
Torp-Pedersen, C. ;
Hansen, P. R. .
JOURNAL OF INTERNAL MEDICINE, 2013, 273 (02) :197-204
[3]
Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries [J].
Ahlehoff, Ole ;
Lindhardsen, Jesper ;
Gislason, Gunnar H. ;
Olesen, Jonas B. ;
Charlot, Mette ;
Skov, Lone ;
Torp-Pedersen, Christian ;
Hansen, Peter R. .
BMC CARDIOVASCULAR DISORDERS, 2012, 12
[4]
Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study [J].
Ahlehoff, Ole ;
Gislason, Gunnar H. ;
Jorgensen, Casper H. ;
Lindhardsen, Jesper ;
Charlot, Mette ;
Olesen, Jonas B. ;
Abildstrom, Steen Z. ;
Skov, Lone ;
Torp-Pedersen, Christian ;
Hansen, Peter Riis .
EUROPEAN HEART JOURNAL, 2012, 33 (16) :2054-2064
[5]
Ahn CS, 2013, J DRUGS DERMATOL, V12, P906
[6]
Membranoproliferative Glomerulonephritis Associated with Psoriasis Vulgaris [J].
Akoglu, Hadim ;
Dede, Fatih ;
Akoglu, Gulsen ;
Gonul, Ipek Isik ;
Odabas, Ali Riza .
RENAL FAILURE, 2009, 31 (09) :858-861
[7]
Akyildiz ZI, 2013, DERMATOLOGY
[8]
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? [J].
Anagnostis, P. ;
Karagiannis, A. ;
Kakafika, A. I. ;
Tziomalos, K. ;
Athyros, V. G. ;
Mikhailidis, D. P. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (02) :197-207
[9]
Effect of 1-Year Anti-TNF-α Therapy on Aortic Stiffness, Carotid Atherosclerosis, and Calprotectin in Inflammatory Arthropathies: A Controlled Study [J].
Angel, Kristin ;
Provan, Sella A. ;
Fagerhol, Magne K. ;
Mowinckel, Petter ;
Kvien, Tore K. ;
Atar, Dan .
AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (06) :644-650
[10]
Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review [J].
Archier, E. ;
Devaux, S. ;
Castela, E. ;
Gallini, A. ;
Aubin, F. ;
Le Maitre, M. ;
Aractingi, S. ;
Bachelez, H. ;
Cribier, B. ;
Joly, P. ;
Jullien, D. ;
Misery, L. ;
Paul, C. ;
Ortonne, J-P ;
Richard, M-A .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 :22-31